Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
- Establishes Plan for Biomarker Study - MONTVALE, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced that it plans to conduct a clinical study of MEM 3454, the Company's lead nicotinic alpha-7 partial agonist, on two biomarker...Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease
-Company to Host Conference Call at 9:00 a.m. EDT- MONTVALE, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced top-line data from the multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MEM 1003, a neuronal...Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
...munity. The Company reported new clinical data for mem 1414, its lead PDE4 inhibitor, demonstrating the c... in humans. In addition, the Company has nominated mem 68626 as the lead development candidate from its 5...r, we are pleased to report that we have nominated mem 68626 as the lead compound in our 5-HT6 antagonist...Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
...ths, highlighted by our positive Phase 2a data for mem 3454 in Alzheimer's disease, the expansion of our schizophrenia development program for mem 3454 with our partner Roche, and the completion of...4996/MEM 63908, and initiate a biomarker study for mem 3454 in schizophrenia." Financial Results For ...Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
... previous client services experience in the Equity Research division of Lehman Brothers. Caryn holds an MBA from the Kellogg School of Management, an mem from Northwestern University, and a BSE in Chemical Engineering from the University of Pennsylvania. http://www.doublehelixdevelopment.c...Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
...E10 inhibitor program and from SMRI related to the mem 1003 program which were recognized in 2007 but not...administrative costs and costs associated with the mem 1003 program. General and administrative expense...ory Pharmaceuticals presented preclinical data for mem 68626, its lead 5-HT6 antagonist, in a poster pres...Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
...nd our Phase 1 program for R4996/MEM 63908, initiating a Phase 2a trial for mem 1414, and advancing our 5-HT6 antagonist program into the clinic." Financ... $3.4 million decrease in costs associated with the clinical development of mem 1003. General and administrative expenses for the quarter ended March 31,...Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
...lpha-7 Receptor Agonist Collaboration with Roche. mem 3454, the lead compound in the Company's ni...y expects to initiate a biomarker study for mem 3454 in schizophrenia this summer, with res...expects to complete its Phase 1 program for mem 63908 and report top-line results in the fourth qu...Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
...will receive approximately $55 million of net offering proceeds, after underwriting discounts and estimated costs. Merriman Curhan Ford & Co. (Amex: mem ) acted as the sole book-running manager in this offering, and Dawson James Securities, Inc. acted as co-manager. Copies of the final prospectus may ...Agendia BV Appoints Clinical and Scientific Advisory Board
...esearch programs and provide critical evaluations from academic and clinical perspectives. Agendia welcomes: Piet Borst (chair), M.D., PhD, CBE, For mem RS, Staff Member and Emeritus Director of the Netherlands Cancer Institute and Professor of Clinical Biochemistry, Amsterdam, The Netherlands Jose Ba...Bionovo Announces Proposed Public Offering of Common Stock
...al Markets Corp. and Canaccord Adams Inc. are acting as joint book-running managers for the proposed offering, with Merriman Curhan Ford & Co. (Amex: mem ) acting as a co-manager. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sal...Culture medium: mem (Sigma) containing 10% (v/v) FBS, 200 µ g/ml G418, L-glutamine, non-essential amino acids
Assay medium: mem (Sigma)
Agonist: Isoproterenol (Sigma)
...
The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies
...EK293 cell line expressing EGF receptor HEK Culture medium: mem (Sigma M2279) containing: 10% (v/v) FBS Geneticin G418...4. Replace the culture medium with 100 µl/well of fresh mem (phenol red free) containing 2.5–5 µg/ml CypHer5E anti-VSV-G an...